157 related articles for article (PubMed ID: 28768977)
1. The First Case of Pseudomonas aeruginosa Bacteremic Pneumonia in a Cancer Patient Receiving Pegfilgrastim.
Morita F; Hirai Y; Suzuki K; Uehara Y; Mitsuhashi K; Takahashi M; Watanabe S; Naito T
Intern Med; 2017; 56(15):2039-2042. PubMed ID: 28768977
[TBL] [Abstract][Full Text] [Related]
2. Pseudogout Attack after Pegfilgrastim Administration in Anaplastic Large Cell Lymphoma.
Hatayama M; Ikuta K; Ishioh M; Saito T; Toki Y; Yamamoto M; Shindo M; Torimoto Y; Okumura T
Intern Med; 2018 Jun; 57(12):1779-1782. PubMed ID: 29434148
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
Donkor KN; Selim JH; Waworuntu A; Lewis K
Ann Pharmacother; 2017 Oct; 51(10):840-847. PubMed ID: 28597691
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on pegfilgrastim in chemotherapy-induced neutropenia.
Frampton JE; Keating GM
BioDrugs; 2005; 19(6):405-7. PubMed ID: 16392893
[TBL] [Abstract][Full Text] [Related]
5. Pegfilgrastim.
Curran MP; Goa KL
Drugs; 2002; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
André N; Kababri ME; Bertrand P; Rome A; Coze C; Gentet JC; Bernard JL
Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
[TBL] [Abstract][Full Text] [Related]
7. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
8. Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients.
Pawloski PA; Larsen M; Thoresen A; Giordana MD
J Oncol Pharm Pract; 2016 Jun; 22(3):423-9. PubMed ID: 25956422
[TBL] [Abstract][Full Text] [Related]
9. LA-EP2006: A Pegfilgrastim Biosimilar.
Hoy SM
BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
[TBL] [Abstract][Full Text] [Related]
10. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
[TBL] [Abstract][Full Text] [Related]
11. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
Kourlaba G; Dimopoulos MA; Pectasides D; Skarlos DV; Gogas H; Pentheroudakis G; Koutras A; Fountzilas G; Maniadakis N
Support Care Cancer; 2015 Jul; 23(7):2045-51. PubMed ID: 25524005
[TBL] [Abstract][Full Text] [Related]
12. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy.
Billingsley CC; Jacobson SN; Crafton SM; Crim AK; Li Q; Hade EM; Cohn DE; Fowler JM; Copeland LJ; Salani R; Backes FJ; O'Malley DM
Int J Gynecol Cancer; 2015 Sep; 25(7):1331-6. PubMed ID: 26067861
[TBL] [Abstract][Full Text] [Related]
14. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.
Yang BB; Savin MA; Green M
Chemotherapy; 2012; 58(5):387-98. PubMed ID: 23296266
[TBL] [Abstract][Full Text] [Related]
15. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.
Renwick W; Pettengell R; Green M
BioDrugs; 2009; 23(3):175-86. PubMed ID: 19627169
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas bacteremia precipitated by ticlopidine-induced neutropenia.
Geletko SM; Melbourne KM; Mikolich DJ
Ann Pharmacother; 1996 Mar; 30(3):246-8. PubMed ID: 8833559
[TBL] [Abstract][Full Text] [Related]
17. A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.
Leung M; Florendo J; Kano J; Marr-Del Monte T; Higgins B; Myers R; Menon T; Jones G
Support Care Cancer; 2015 Jun; 23(6):1669-77. PubMed ID: 25421443
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study evaluating the safety of administering pegfilgrastim on the final day of 5-fluorouracil continuous intravenous infusion.
Draper AS; Lafollette J; Kim C; Wu CS
J Oncol Pharm Pract; 2021 Jul; 27(5):1159-1164. PubMed ID: 32762293
[TBL] [Abstract][Full Text] [Related]
19. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
Waladkhani AR
Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
[TBL] [Abstract][Full Text] [Related]
20. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
